Morepen Labs Sets May 22 for FY26 Results; Q3 Shows Strong Growth

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorVihaan Mehta|Published at:
Morepen Labs Sets May 22 for FY26 Results; Q3 Shows Strong Growth
Overview

Morepen Laboratories Ltd. will hold a board meeting on May 22, 2026, to approve its audited financial results for the fiscal year 2026. The company also announced a trading window closure from May 23-24, 2026. Investors are anticipating the full-year performance report.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Morepen Laboratories to Approve FY26 Results on May 22

Announcement Details

Morepen Laboratories Ltd. announced its Board of Directors will meet on May 22, 2026, to approve the audited standalone and consolidated financial results for the fiscal year ending March 31, 2026. The company also stated its trading window for securities will be closed from May 23 to May 24, 2026.

Significance for Investors

This announcement marks the final stages of the financial year's reporting cycle. Investors are keenly awaiting the audited full-year performance figures, which will offer a comprehensive view of the company's financial health, profitability, and operational efficiency throughout FY26.

Company Profile and Q3 Performance

Morepen Laboratories operates in the pharmaceutical sector, focusing on Active Pharmaceutical Ingredients (APIs), finished formulations, and diagnostics. Its well-known brands include Burnol and Lemolate. For the third quarter of FY26, the company reported a healthy 10.6% year-on-year increase in consolidated revenue, reaching ₹385 crore. Profit After Tax also climbed to ₹41 crore, up from ₹30 crore in the same period last year.

Trading Window and Shareholder Action

Shareholders and investors will now await the official declaration of the full-year financial results. The trading restriction period means company insiders cannot trade in its shares until the results are made public.

Competitor Landscape

Morepen Laboratories operates in a competitive pharmaceutical landscape. Key peers include Divi's Laboratories Ltd., a major player in APIs and custom synthesis, and Aarti Drugs Ltd., which focuses on APIs and pharmaceutical intermediates. Divi's Laboratories reported robust Q3 FY26 financials with revenue of ₹2,226 crore and PAT of ₹613 crore, while Aarti Drugs posted Q3 FY26 revenue of ₹653 crore and PAT of ₹42 crore.

Key Focus Areas Ahead

  • The formal release of Morepen Laboratories' audited standalone and consolidated financial results for FY26 on May 22, 2026.
  • Analysis of the full-year revenue, profit, and margin trends.
  • Management's commentary on future outlook and strategic priorities.
  • Morepen's performance compared to peers like Divi's Laboratories and Aarti Drugs.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.